Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-02
2010-06-01
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07727724
ABSTRACT:
A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.
REFERENCES:
patent: 6716581 (2004-04-01), Lenz et al.
patent: 2004/0067519 (2004-04-01), Lenz et al.
patent: 2006/0094012 (2006-05-01), Lenz et al.
patent: 2006/0115827 (2006-06-01), Lenz
patent: 2007/0207486 (2007-09-01), Lenz
patent: 2007/0218487 (2007-09-01), Lenz
patent: WO 2007/064957 (2007-06-01), None
patent: WO 2008/144512 (2008-11-01), None
Nagashima et al (Proc ASCO, 2006, 24:3533: abstract).
Escayg et al (Am J Hum Genet, 2001, 68: 866-873).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Douglass et al. (1986) “Survival after Postoperative Combination Treatment of Rectal Cancer,”N. Eng. J. Med. 315:1294-1295.
Grolleau et al. (2001) “A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels,”J. Neurophysiology85:2293-2297.
Jemal et al. (2005) “Cancer Statistics, 2005,”Cancer J. Clin. 55(1):10-30.
Kastan (1991) “Participation of p53 Protein in the Cellular Response to DNA Damage,”Cancer Res. 51:6304-6311.
Lenz (2004) “The Use and Development of Germline Polymorphisms in Clinical Oncology,”J. Clin. Oncol. 22(13):2519-2521.
Levine (1992) “The p53 Tumor-Suppressor Gene,”N. Engl. J. Med. 326:1350-1352.
Machover et al. (1996) “Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines,”Ann. Oncol. 7(1):95-98.
Nunez (1996) “Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells,”Rad. Onc. 39:155-165.
Park et al. (2006) “Determinants of chemosensitivity in gastric cancer,”Curr. Opin. Pharma. 6(4):337-344.
Rougier and Lepre (2005) “Metastatic Colorectal Cancer: First- and Second-Line Treatment in 2005,”Semin. Oncol. 32(6 Suppl. 8):15-20.
Yan and Beckman (2005) “Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development,”Biotechniques39:565-568.
Yanagisawa et al. (1998) “Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10,”Oral Oncol. 34:524-528.
Zhang et al. (2006) “Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab,”Pharma. and Genomics16(7):475-483.
U.S. Appl. No. 09/715,764, filed Nov. 15, 2000, Lenz et al.
Viguier et al. (2005) “ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer”Clin. Cancer Res. 11:6212-6217.
PCT/US2008/000650, Jan. 17, 2008, Lenz.
PCT/US2008/000715, Jan. 17, 2008, Lenz.
PCT/US2008/051527, Jan. 18, 2008, Lenz et al.
PCT/US2008/000651, Jan. 17, 2008, Lenz et al.
PCT/US2008/000661, Jan. 17, 2008, Lenz et al.
PCT/US2008/000685, Jan. 17, 2008, Lenz.
PCT/US2008/000660, Jan. 17, 2008, Lenz et al.
Escayg et al. (2001) “A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus-and prevalence of variants in patients with epilepsy”Am. J. Hum. Genet. 68:866-873.
Grolleau et al. (2001) “A possible explantation for a neurotoxic effect of the anticancer agent oxaliplatin on seuronal voltage-gated sodium channels”J. Neurophysiol. 85:2293-2297.
Fraser et al. (2005) “Voltage-gated sodium channels expression and potentiation of human breast cancer metastasis”Clin. Cancer Res. 11:5381-5389.
Iqbal et al. (2003) “Targeted therapy and pharmacogenomic programs” Cancer 97:2076-2082.
PCT/US07/63219—International Search Report.
U.S. Appl. No. 12/110,044, filed Apr. 25, 2008, Lenz et al.
U.S. Appl. No. 12/095,493, filed Nov. 30, 2006, Lenz.
PCT/US2008/066454, Jun. 10, 2008, Lenz.
Douillard et al. (2000) “Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial ” Lancet 355:1041-1047.
Gaber et al. (2003) “Retrospective analysis of 5-FU/LV/CPT-11 2 weeks on/1 week off (IFL2), a pilot study,” Proc ASCO 22:1515.
Goldberg et al. (2004) “A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients with Previously Untreated Metastatic Colorectal Cancer”J. Clin. Oncol. 22(1):23-30.
Heidelberger et al. (1957) “Fluorinated pyrimidines: A new class of tumor inhibitor compounds” Nature 179:663-666.
Iqbal and Lenz (2001) “Determinants of prognosis and response to therapy in colorectal cancer,”Curr. Oncol. Rep. 3(2)102-108.
Iqbal et al. (2003) “Molecular predictors of treatment and outcome in colorectal cancer,” Curr Gastroenterol Rep 5(5):399-405.
Iqbal et al. (2004) “Tailored chemotherapy for colorectal cancer: a new approach to therapy” Cancer Invest. 22(5):762-773.
Iqbal et al. (2005) “Individualized Chemotherapy Based on Genetic and Genomic Profiling,” Curr Colorectal Cancer Rep 1(2): 91-102.
Lenz (2002) “Pharmacogenetic determinants of clinical outcome and toxicity in colon cancer,”Eur J Cancer38(Suppl. 7):S68 #212.
Lenz (2003) “Pharmacogenomics in colorectal cancer,”Semin Oncol. 30(4 Suppl 15):47-53.
Lenz et al. (1997) “Molecular markers as indicators of response and outcome in primary gastric cancer”Prog Gastric Cancer Res2:1295-1300.
Lenz et al. (2002) A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Proc ASCO 21:513.
Llombart-Bosch et al. (eds.)New Trends in Cancer for the 21stCentury 2ndEdition, Series: Advances in Experimental Medicine and Biology, 2006, vol. 587, Chapter 18: Pharmacogenomics and Colorectal Cancer, pp. 211-231, Springer.
Moertel (1994) “Chemotherapy for colorectal cancer”N. Engl. J. Med. 330:1136-1142.
Nagashima et al. (2006) “Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin”Proc ASCO24:3533: Abstract.
Nagashima et al. (2006) “Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin”Proc ASCO24:3533: Poster: [Retrieved online on Jul. 21,2008 at the following: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst—detail—view&conflD=40&abstractID=31130].
Park et al. (2003) “Tailoring chemotherapy in advanced colorectal cancer,” Curr Opin Pharmacol 3(4):378-385.
Saltz et al. (2000) “Irinotecan plus fluoruracil and leucovorin for metastatic colorectal cancer”N. Engl. J. Med. 343(13):905-914.
Stoehlmacher and Lenz (2003) “Implications of genetic testing in the management of colorectal cancer,”Am. J. Pharmacogenomics3(2):73-88.
Stoehlmacher et al. (2004) “A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer,”Br. J. Cancer91(2):344-54.
Vallboehmer et al. (2006) “Molecular Determinants of lrinotecan Efficacy,”International Journal of Cancer119(10):2435-42. Nov 15.
Yang et al. (2005) “Molecular prognostic factors of irinotecan efficacy,”Proc ASCO23:3621.
Yun et al. (2004) “Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin,”Proc ASCO23:3519.
Aeder Sean E
Foley & Lardner LLP
Konski Antoniette F.
University of Southern California
LandOfFree
Polymorphisms in voltage-gated sodium channel α... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphisms in voltage-gated sodium channel α..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphisms in voltage-gated sodium channel α... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153544